North American Neuroendocrine Tumor Society presents:

2009 Neuroendocrine Tumor Symposium Abstracts

NOTICE - Your Javascript is disabled!
Javascript needs to be enabled in order to search the abstracts and receive content updates. Click to read instructions on enabling your Javascript »

Index of Abstracts:

B1	Identification of a Novel Raf-1 Activating Drug That Inhibits Gastrointestinal Carcinoid Growth Mackenzie R. Cook, Scott N. Pinchot, Renata Jaskula-Sztul, Jie Luo, Muthusamy Kunnimalaiyaan, Herbert Chen

B2	Discordant Expression of Proliferating Cell Nuclear Antigen (PCNA) and Ki-67 Antigen in Carcinoid and Pancreatic Neuroendocrine Tumors (C&PET) Likely Indicates Enhanced DNA Repair Malik E. Juweid, Sergei Syrbu, Barry DeYoung, Sue O’Dorisio, Thomas O’Dorisio

B3	New Biomarkers in Neuroendocrine Tumors: A Retrospective Study of Their Diagnostic and Prognostic Value Department of Clinical Chemistry, Department of Medical Oncology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

B4	Angiogenesis Markers After Chemoembolization of Liver Metastases in Patients with Neuroendocrine Tumour Catharina M. Korse, Babs G. Taal, Johannes M.G. Bonfrer

B5	Somatostatin Receptor Activation by Agonist-like Antibodies can Reverse miR-200c/ZEB1 Dependent Cell Dedifferentiation and Increase Cell Death in Neuroendocrine Tumor Cells Frank Leu, Minesh Nandi, Chung Wong

B6

Discovery of G Protein Coupled Receptor Tumor Signatures and Identification of Positron Emission Tomography Imaging Targets in Ileal and Pancreatic Neuroendocrine Tumors

Molly E. Martin, Daniel Calva-Cerqueira, Blanca Schafer, Whitney Leverich, Michael K. Schultz, Damon C. Shutt, Thomas M. O’Dorisio, M. Sue O’Dorisio, and James Howe

B7	Distinct mTOR Pathway Activity in Neuroendocrine Tumors of the Pancreas and Small Intestine Revealed by Immunohistochemical Analysis Eric Nakakura, Melissa Wong, Yucheng Wang, Gioia Iezza, Marlene Zuraek, Xiaochen Yuan, David Donner, Douglas Hanahan, Robert Warren, Emily Bergsland

B8

Discovery and Validation of a Novel Set of Putative Progression Markers in Well-Differentiated Primary Pancreatic Endocrine Carcinomas

Aejaz Nasir, SM McCarthy, Nelly A Nasir, Dung-Tsa Chen, Deepak Agrawal, Jihad Skaf, Mike Gruidl, Gregory C Bloom, Steven Eschrich, Nancy M Gardner, Jonathan Strosberg, Pamela Hodul, Emily Zeringer, Steven Enkemann, Domenico Coppola, Mokenge P Malafa ., Timothy J Yeatman, Larry K Kvols

B9

RUNX1T1 and Palladin Outperform Pathologic Criteria of Malignancy in Predicting

Aejaz Nasir, Evita B Henderson-Jackson, James Helm, Jonathan Strosberg, Nelly A Nasir, Pamela Hodul, Masoumeh Ghayouri, Barbara A. Centeno, Ardeshir Hakam, Mokenge P Malafa, Timothy J Yeatman Domenico Coppola, Larry K Kvols

B10	Palladin is a Reliable Marker of Liver Metastasis in Primary Pancreatic Endocrine Neoplasms Aejaz Nasir, Evita B Henderson-Jackson, James Helm, Jonathan Strosberg, Nelly A Nasir, Domenico Coppola, Larry K Kvols

B11	Metastasis-associated Gene Products and Liver Metastases in Aejaz Nasir, James Helm, Jonathan R. Strosberg, Leslie M. Turner, Evita B Henderson-Jackson, Naiel Hafez, Nelly A. Nasir, Ardeshir Hakam, Domenico Coppola, Larry K. Kvols

B12

Development of a Highly Sensitive and Specific Carboxy-terminal Human Pancreastatin Assay to Monitor Neuroendocrine Tumor Behavior

Thomas M. O’Dorisio, Siegfried R. Krutzik, Eugene A. Woltering, Erika Lindholm, Saju Joseph, Yi- Zarn Wang, J. P. Boudreaux, Aaron I. Vinik, V.L.W. Go, James R. Howe, Thor Halfdanarson, M. Sue O’Dorisio, Gregg Mamikunian

B13	Development of Gallium-68 Labeled Neuropeptide Analogs for Imaging NET by Positron Emission Tomography Michael K. Schultz, Damon C. Shutt, Nicholas A. Weiland, Neja White, Blanca Schafer, Molly E. Martin, Laura L. Boles Ponto, Susan Walsh, Thomas M. O’Dorisio, and Sue O’Dorisio

B14

A Large-scale SNP Evaluation Reveals an Association of a TSC2 SNP with Sporadic Neuroendocrine Tumor Risk

Monica Ter-Minassian, Zhaoxi Wang, Kofi Asomaning, Michael Wu, Chen-Yu Liu, Jessica Paulus, Geoffrey Liu, Penny Bradbury, Li Su, Christine Frauenhoffer, Susanne M. Hooshmand, Jamie Silver, Immaculata De Vivo, Xihong Lin, David C. Christiani, Matthew H. Kulke

C1

An Open-label, Phase II Study Evaluating the Safety and Efficacy of PTK787/ZK222584 in Patients with Metastatic Neuroendocrine Tumors that Have Evidence of Progressive Disease or an Increase in Disease Related Syndrome Symptoms

Lowell B. Anthony, Maria M. Chester, Bernard J. Brown, Stacy L. Michael, Jacky R. Seward, M. Sue O’Dorisio, Thomas M. O’Dorisio

C2	Health-related Quality of Life of Patients with Neuroendocrine Tumor Compared to the United States General Population Jennifer L. Beaumont, Zhimei Liu, Seung Choi, James C. Yao, David Cella

C3	Gluteal Intramuscular Injections: Techniques Associated with Successful Octreotide LAR Injection April E. Boyd, Colleen C. Leary, James P. Brook, Valentine G. Boving, Cecile G. Dagohoy, Linda L. DeFord, Jeana L. Garris, Jeannette E. Mares, Alexandria T. Phan, James C. Yao

C4	LX1032: A Novel Agent to Reduce Serotonin In Carcinoid Syndrome Philip Brown, Kenny Frazier, Shanna Jackson, Anne Turnage, Qingyun Liu

C5	Surgical Management of Neuroendocrine Tumors Metastatic to the Liver Scott Celinski MD, Jennifer Steel PhD, Kevin Tri Nguyen MD PhD, J. Wallis Marsh MD, David A. Geller MD, Richard Raizman MD, Allan Tsung MD, T. Clark Gamblin MD, MS

C6

One year Follow-up for the Phase I MTD study of Ultratrace Iobenguane I 131 in Patients with Malignant Pheochromocytoma/Paraganglioma (Pheo)

R. Edward Coleman, Stanley J. Goldsmith, Richard B. Noto, Kimberly R. Pearson, Katherine A. Kacena, John A. Barrett, Norman D. LaFrance, John W. Babich Corresponding author

C7

Transarterial Chemoembolization in Patients with Metastatic Carcinoid Amenable to Cytoreductive Hepatectomy Results in Improved Survival but Similar Regional Disease Control Compared to Those Deemed Inoperable

Feria-Arias, Enrique; Arrese, David; Hatzaras, Ioannis; Schmidt, Carl; Shah, Manisha; Bloomston, Mark

C8	Gender Related Issues in Gluteal Intramuscular Injections Jeana L. Garris, Linda L. DeFord, Cecile G. Dagohoy, Colleen C. Leary, Valentine G. Boving, James P. Brook, Jeannette E. Mares, April E. Boyd, Alexandria T. Phan, James C. Yao

C9	Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs): A Single-Center Case Control Study Thorvardur R. Halfdanarson, William R. Bamlet, Timothy J. Hobday, Robert R. McWilliams, Gloria M. Petersen.

C10	Early CgA Response as Predictor of Outcome Following Everolimus Therapy Among Patients with Low- to Intermediate- Grade Neuroendocrine Carcinoma: Carmen B. Jacobs, Alexandria T. Phan, Robert A. Wolff, Funda Meric-Bernstam, James C. Yao

C11

A Prospective Trial on the Effect of Body Mass Index and Gender on Plasma Octreotide Levels in Patients Undergoing Long Term Therapy With Octreotide LAR

Saju Joseph, MD, Gang Li, PhD, Erika Lindholm, MD, Ying Zhou, MS, Vay Liang W. Go, MD, Aaron I. Vinik, MD, PhD, Thomas M. O’Dorisio, MD, Gregg Mamikunian, MS and Eugene A. Woltering, MD, FACS

C12

The Clinical Utility of Ki-67 in Assessing Tumor Biology and Aggressiveness in Patients with Appendiceal Carcinoids

Eric Liu, MD, Dana A. Telem, MD, John Hwang, BA, Richard R. P. Warner, MD, Steven H. Dikman, MD, and Celia M. Divino, MD, FACS Department of Surgery, Department of Internal Medicine, Section of Gastroenterology, and Department of Pathology, Mount Sinai School of Medicine, New York, NY

C13	Extensive Retroperitoneal Carcinoid Involving the Mesenteric Vasculature Does Not Preclude Effective Cytoreduction John M. Lyons, III, Erica Lindholm, Yi-Zarn Wang, Jessica L. Thomson, Lowell B. Anthony, Eugene A. Woltering, Daniel J. Frey, Saju Joseph, Thiagaran Ramacharan and J. Philip Boudreaux

C14	Gluteal Intramuscular Injections: CT Evaluation of Factors Associated with Success and Failure Jeannette E. Mares, Cecile G. Dagohoy, Colleen C. Leary, Linda L. DeFord, Valentine G. Boving, James P. Brook, Jeana L. Garris, April E. Boyd, Alexandria T. Phan, James C. Yao

C15

Is Patient Age Associated with Improved Survival after Transarterial Chemoembolization (TACE) for Unresectable Neuroendocrine Tumor (NET) Metastasis?

Ruhina Mehra, Kevin Tri Nguyen MD, PhD, Jennifer Steel PhD, Nikhil Amesur MD, Richard Raizman MD, Scott Celinski MD, Allan Tsung MD, T. Clark Gamblin MD, MS

C16	Identification of Unknown Primary Tumors in Patients with Neuroendocrine Liver Metastases Sam C. Wang, Justin R. Parekh, Marlene B. Zuraek, Alan P. Venook, Emily K. Bergsland, Robert S. Warren, Eric K. Nakakura

C17	RUNX1T1: A Novel Predictor of Liver Metastasis in Primary Pancreatic Aejaz Nasir, James Helm, Leslie M. Turner, Evita B Henderson-Jackson, Jonathan R. Strosberg, Nelly A. Nasir, Ardeshir Hakam, Domenico Coppola, Larry K. Kvols

C18	Primary Gastro-entero-pancreatic Poorly Differentiated Neuroendocrine Carcinoma: Clinico-pathologic and Survival Analysis in 68 Cases Aejaz Nasir, Mulazim H. Bukhari, Elizabeth Byron, Jonathan R. Strosberg, Evita B. Henderson-Jackson, Domenico Coppola, Larry K. Kvols

C19	Neuroendocrine Tumors in Children and Young Adults: Incidence, Survival, and Prevalence in the United States P. Navalkele, M. O'Dorisio, T. M. O'Dorisio, C. F. Lynch

C20	Gastroduodenal Ulceration Associated with Radioembolization for the Treatment of Liver Malignancies; a Newly Observed Complication Steven Naymagon, Richard R.P. Warner, Kalpesh Patel, Josef Machac, Joshua L. Weintraub, Michelle K. Kim

C21	Phase I Trial of 90Y-DOTA-tyr3-Octreotide in Children and Young Adults M. Sue O’Dorisio, Yusuf Menda, Stacy Michael, Simon Kao, Geetika Khanna, Mary Connelly, John Babich, Thomas O’Dorisio, David Bushnell, M.D., Mark Madsen

C22	Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs): Ike Onwere, Thomas O’Dorisio, Sue M. O’Dorisio, Barry DeYoung, Menda Yusuf

C23	Phase II Study of Temozolomide for Relapsed Sensitive or Refractory M. Catherine Pietanza, William D. Travis, Timothy A. Chan, Michelle S. Ginsberg, Andrei Holodny Mark G. Kris, Lee M. Krug

C24

Sunitinib versus Placebo for the Treatment of Progressive, Well-Differentiated Pancreatic Islet Cell Tumors: A Phase III, Randomized, Double-Blind Trial

Eric Raymond, Jean-Luc Raoul, Patricia Niccoli, Yung-Jue Bang, Ivan Borbath, Catherine Lombard-Bohas, Peter Metrakos, Dongrui-Ray Lu, Carolyn Blanckmeister, Aaron Vinik

C25	Phase I study of Seneca Valley Virus (SVV-001), A Replication Competent Oncolytic Virus, in Patients with Carcinoid Cancers CM Rudin, N Senzer, J Stephenson, K Burroughs N Senzer, T Williams

C26	Initial Evaluation of Patients with NETS: A Prospective Evaluation of the Influence of Intensive Pre-Visit Counseling Pamela Ryan BSN RN, Jarret Brashear BS, Yi-Zarn Wang MD, Lowell B. Anthony MD, J. Philip Boudreaux MD, Saju Joseph MD, Richard Campeau MD and Eugene A. Woltering MD

C27	First-Line Treatment of Metastatic Pancreatic Endocrine Carcinomas with Capecitabine and Temozolomide Jonathan Strosberg MD, Junsung Choi MD, Aejaz Nasir MD, Larry Kvols MD

C28	Phase II Study of Sunitinib Following Hepatic Artery Embolization for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) H. Lee Moffitt Cancer Center, Tampa, FL

C29	The Antiproliferative Effect of Octreotide in Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) Jonathan Strosberg MD and Larry Kvols MD

C30

Initial Impact of a Systematic Multidisciplinary Approach on the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumor

Department of Endocrinology & Diabetes Mellitus, St Vincent’s University Hospital, Dublin, Ireland Department of Pathology & Laboratory Medicine, St Vincent’s University Hospital, Dublin, Ireland Department of Radiology, St Vincent’s University Hospital, Dublin, Ireland Liver Transplant Unit, St Vincent’s University Hospital, Dublin, Ireland Department of Medical Oncology, St Vincent’s University Hospital, Dublin, Ireland Department of Gastroenterology, St James’s Hospital, Dublin, Ireland

C31	The Utility of F-18 DOPA PET/CT in Identifying Unknown Site of Primary Damita Thomas MD, Yusuf Menda MD, David Bushnell MD, Thomas O’Dorisio MD

C32	Relationship Between Quality Of Life And Health-Related Measures Including Etta Vinik, Maria Silva, Aaron Vinik

C33	Lymphatic Mapping Helps Define Resection Margins for Midgut Carcinoids Wang, Yi-Zarn DDS, MD, Joseph, Saju MD, Lindholm, Erika BSE, Lyons, John MD, Boudreaux, J. Philip MD, Woltering, Eugene A. MD

C34	Pasireotide LAR in Metastatic Carcinoid Tumors: A Randomized Phase I Study Edward. M. Wolin, Larry K. Kvols, Shereen Ezzat, Walter I. Kocha, Brigitte Weisshaar, Ke Hu, Pharis Mohideen, Eric Van Cutsem

C35

Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial

James C. Yao, Catherine Lombard-Bohas, Eric Baudin, Larry K. Kvols, Philippe Rougier, Philippe Ruszniewski, Sakina Hoosen, Jessica St. Peter, Tomas Haas, David Lebwohl, Eric Van Cutsem, Matthew Kulke, Timothy J. Hobday, Thomas M. O'Dorisio, Manisha H. Shah, Guillaume Cadiot, Gabriele Luppi, James A. Posey, Bertram Wiedenmann for the RADIANT- Study Group